

## 2024 Pediatric and Neonatal Antibigram

Gram-Positive Organisms					
2024 Pediatric & Neonatal Antibiogram Inpatients Only	*Denotes anaerobic coverage	Staph aureus - MSSA (methicillin sensitive)	Staph aureus -MRSA (methicillin resistant)	Staphylococcus epidermidis	Enterococcus faecalis
# of isolates analyzed		170	100	62	56
% Susceptible					
Ampicillin	*				100%
Ceftaroline		100%	100%		
Clindamycin	*	77%	90%	55%	
Daptomycin		100%	100%		
Gentamicin Synergy (high level)					89%
Levofloxacin					100%
Linezolid		100%	100%	100%	98%
Nitrofurantoin		99%	100%	100%	100%
Oxacillin		100%	0%	44%	
Penicillin G		0%	0%	0%	100%
Streptomycin Synergy (high level)					96%
Tetracycline/Doxycycline	*	96%	98%	74%	
Trimethoprim-sulfa		93%	77%	83%	
Vancomycin		100%	100%	100%	100%

<p style="text-align: center;">This antibiogram has been prepared from SCC SOFT LIS.</p> <p style="text-align: center;">This antibiogram contains 2 years of organisms isolated in 2022-2023</p> <p style="text-align: center;">Only the first isolate per patient is included in this data.</p> <p style="text-align: center;">Denotes activity against anaerobes. Anaerobes are not tested for susceptibility profiles at WakeMed.</p>	<p style="text-align: center;">23% of Inpatient Pediatric MSSA are Clindamycin Inducible Resistant</p> <p style="text-align: center;">3% of Inpatient Pediatric MRSA are Clindamycin Inducible Resistant</p> <p style="text-align: center;">Data is for inpatient wards for Pediatrics (4E/PICU) and Neonatal (RNIC and all WakeMed Nurseries)</p>
--	--

**Pediatric Antibiograms are published every 2 years by the Microbiology Lab and the Antimicrobial Stewardship Program. 919-350-8075**